Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.

doi:10.1089/jir.1995.15.611

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research - 1 Jul 1995

Hwang S J, Chan C Y, Lu R H, Wu J C, Lee S D

Abstract excerpt

To evaluate the efficacy of recombinant interferon (IFN) alpha 2b in the treatment of Chinese patients with chronic hepatitis C, a randomized controlled trial was conducted in 50 chronic hepatitis C patients: 25 patients received 3 million units of subcutaneously injected recombinant IFN-alpha 2b...

Topics

Alanine Transaminase
Antiviral Agents
Base Sequence
China
Chronic Disease
Drug Administration Schedule
Evaluation Studies as Topic
Female
Genotype
Hepacivirus
Hepatitis C
Humans
Injections, Subcutaneous
Interferon alpha-2
Interferon-alpha
Male
Middle Aged
Molecular Sequence Data

Source

Open in PubMed

Identifiers

PMID: 7553231
DOI: 10.1089/jir.1995.15.611

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-7553231-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics